While the U.S. Food and Drug Administration sets the federal framework for pharmaceutical and bioscience regulation, states play a decisive role in shaping how these industries grow and operate within their borders. State legislators and executive leaders influence where biotech firms locate, how research and development are incentivized through tax policy, and whether states have the skilled workforce needed to support laboratory and manufacturing jobs.

For state officials, the challenge is twofold: advancing patient care and health outcomes for residents while also using economic development, workforce, and fiscal policy tools to attract and sustain high-growth life sciences industries. Public-private partnerships can be powerful drivers of innovation and investment, but they also require careful oversight to ensure states are balancing competitiveness with fiscal responsibility and preserving revenue needed to support core state priorities and services.

As state leaders confront these interconnected challenges, a set of policy considerations emerges. States are increasingly exploring initiatives that improve outcomes for chronic conditions such as cancer, heart disease, and vascular disease — often through public health investments, research partnerships, and access-to-care strategies. At the same time, governors and legislators are working to align higher education and workforce systems by fostering partnerships between community colleges, state universities, and pharmaceutical and biotechnology companies to build the next generation of lab technicians and research professionals.

State policymakers also face decisions about how to support emerging life sciences companies through investment and innovation tax credits while maintaining fairness and accountability in the use of public funds. Balancing these economic development strategies with other pressing needs is a central responsibility for legislatures and budget officials. Beyond incentives, states directly shape the operating environment for bioscience firms through regulatory oversight, permitting, and land-use decisions — placing state governments at the center of both industry growth and public interest protection.

This report builds on themes highlighted in The U.S. Bioscience Industry: A Powerful Engine for State Economies. It also complements existing research (BIO & CSBA; UMR; Teconomy, CSBA, & BIO; LSWC & Teconomy; Alliance for Building Better Medicine) on the importance of patient care systems and the pharmaceutical and biotechnology sectors for states. Additionally, it explores new information regarding state legislative measures relating to patients and healthcare that were introduced and passed in 2025 and 2026.

This analysis examines trends in the cost of providing healthcare, considers how states might direct resources to medical education and research labs, and shares case studies of states that have successfully improved patient care. It further examines which states provide substantial tax incentives for bioscience firms, boast thriving biopharma ecosystems, cultivate talented workforces, and advance medical discoveries that benefit residents. Finally, the report includes additional discussion of venture capital opportunities and the enormous economic impact that patient care, pharmaceutical, and bioscience industries can have for states.